June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Safety of intravitreal quinupristin / dalfopristin in an animal model
Author Affiliations & Notes
  • Veronica Giordano
    Retina, Asociación para evitar la Ceguera en Mexico, Distrito Federal, Mexico
  • Sergio Hernandez-Da Mota
    Retina, Asociación para evitar la Ceguera en Mexico, Distrito Federal, Mexico
  • Jose Luis Guerrero-Naranjo
    Retina, Asociación para evitar la Ceguera en Mexico, Distrito Federal, Mexico
  • Tania Adabache Guel
    Retina, Asociación para evitar la Ceguera en Mexico, Distrito Federal, Mexico
  • Samantha Salinas Longoria
    Retina, Asociación para evitar la Ceguera en Mexico, Distrito Federal, Mexico
  • Sonia Corredor-Casas
    Retina, Asociación para evitar la Ceguera en Mexico, Distrito Federal, Mexico
  • Guillermo Salcedo-Villanueva
    Retina, Asociación para evitar la Ceguera en Mexico, Distrito Federal, Mexico
  • Juan Manuel Jimenez-Sierra
    Retina, Asociación para evitar la Ceguera en Mexico, Distrito Federal, Mexico
  • Virgilio Morales-Canton
    Retina, Asociación para evitar la Ceguera en Mexico, Distrito Federal, Mexico
  • Footnotes
    Commercial Relationships Veronica Giordano, None; Sergio Hernandez-Da Mota, None; Jose Luis Guerrero-Naranjo, Neurotech (F); Tania Adabache Guel, None; Samantha Salinas Longoria, None; Sonia Corredor-Casas, None; Guillermo Salcedo-Villanueva, None; Juan Manuel Jimenez-Sierra, None; Virgilio Morales-Canton, Clearside Biomedical (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1966. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Veronica Giordano, Sergio Hernandez-Da Mota, Jose Luis Guerrero-Naranjo, Tania Adabache Guel, Samantha Salinas Longoria, Sonia Corredor-Casas, Guillermo Salcedo-Villanueva, Juan Manuel Jimenez-Sierra, Virgilio Morales-Canton; Safety of intravitreal quinupristin / dalfopristin in an animal model. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1966.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the retinal toxicity of varying doses of quinupristin-dalfopristin when injected intravitreally in rabbits.

Methods: Design: Randomized controlled trial. Twenty-two rabbits were used for this study and divided into four groups. Four concentrations of quinupristin-dalfopristin were prepared: group 1: 0.01mg/0.1ml; group 2: 0.1mg/0.1ml, group 3: 1mg/0.1ml and group 4: 10mg/0.1ml. Each concentration was injected intravitreally in one eye of each of six rabbits of each group; 0.1 mL volume of sterile balanced saline solution was injected into the contralateral eyes. Basal and weekly ERG (measuring mesopic implicit times and amplitudes), fundus photographs and macular OCT were performed and the animals were observed for 4 weeks for signs of inflammation or toxicity. At the end of follow-up the animals were killed. The enucleated eyes were prepared for histologic evaluation of retinal toxicity.

Results: There was a statistically significant difference between all groups (Friedman test, p < 0.01). In groups 1 and 2 there were no statistically significant differences between basal and follow-up measures of each group and between them (Wilcoxon rank-sum test, p =1.0). In contrast, comparisons of amplitude and implicit times of groups 3 and 4 showed high statistically significant differences between basal and follow-up measures, as well as between follow-up measures of injected and control eyes (p < 0.01). Groups 1 and 2 showed no ERG changes compared to groups 3 and 4 (Wilcoxon rank-sum test, p < 0.01). Only groups 3 and 4 revealed severe vitreous inflammation and hemorrhage. There were no significant histopathological changes in groups 1 and 2.

Conclusions: Intravitreal quinupristin/dalfopristin doses of 0.01mg/0.1ml and 0.1mg/0.1ml showed no signs of retinal toxicity.

Keywords: 688 retina • 503 drug toxicity/drug effects  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×